BACKGROUND: Evidence for vaccine effectiveness (VE) against influenza-associated pneumonia has varied by season, location, and strain. We estimate VE against hospitalization for radiographically identified influenza-associated pneumonia during 2015-2016 to 2017-2018 seasons in the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN). METHODS: Among adults aged ≥18 years admitted to 10 US hospitals for acute respiratory illness (ARI), clinician-investigators used keywords from reports of chest imaging performed during 3 days around hospital admission to assign a diagnosis of "definite/probable pneumonia." We used a test-negative design to estimate VE against hospitalization for radiographically identified laboratory-confirmed influenza-associated pneumonia, comparing reverse transcriptase-polymerase chain reaction-confirmed influenza cases with test-negative subjects. Influenza vaccination status was documented in immunization records or self-reported, including date and location. Multivariable logistic regression models were used to adjust for age, site, season, calendar-time, and other factors. RESULTS: Of 4843 adults hospitalized with ARI included in the primary analysis, 266 (5.5%) had "definite/probable pneumonia" and confirmed influenza. Adjusted VE against hospitalization for any radiographically confirmed influenza-associated pneumonia was 38% (95% confidence interval [CI], 17-53%); by type/subtype, it was 74% (95% CI, 52-87%) influenza A (H1N1)pdm09, 25% (95% CI, -15% to 50%) A (H3N2), and 23% (95% CI, -32% to 54%) influenza B. Adjusted VE against intensive care for any influenza was 57% (95% CI, 19-77%). CONCLUSIONS: Influenza vaccination was modestly effective among adults in preventing hospitalizations and the need for intensive care associated with influenza pneumonia. VE was significantly higher against A (H1N1)pdm09 and was low against A (H3N2) and B.
BACKGROUND: Evidence for vaccine effectiveness (VE) against influenza-associated pneumonia has varied by season, location, and strain. We estimate VE against hospitalization for radiographically identified influenza-associated pneumonia during 2015-2016 to 2017-2018 seasons in the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN). METHODS: Among adults aged ≥18 years admitted to 10 US hospitals for acute respiratory illness (ARI), clinician-investigators used keywords from reports of chest imaging performed during 3 days around hospital admission to assign a diagnosis of "definite/probable pneumonia." We used a test-negative design to estimate VE against hospitalization for radiographically identified laboratory-confirmed influenza-associated pneumonia, comparing reverse transcriptase-polymerase chain reaction-confirmed influenza cases with test-negative subjects. Influenza vaccination status was documented in immunization records or self-reported, including date and location. Multivariable logistic regression models were used to adjust for age, site, season, calendar-time, and other factors. RESULTS: Of 4843 adults hospitalized with ARI included in the primary analysis, 266 (5.5%) had "definite/probable pneumonia" and confirmed influenza. Adjusted VE against hospitalization for any radiographically confirmed influenza-associated pneumonia was 38% (95% confidence interval [CI], 17-53%); by type/subtype, it was 74% (95% CI, 52-87%) influenza A (H1N1)pdm09, 25% (95% CI, -15% to 50%) A (H3N2), and 23% (95% CI, -32% to 54%) influenza B. Adjusted VE against intensive care for any influenza was 57% (95% CI, 19-77%). CONCLUSIONS: Influenza vaccination was modestly effective among adults in preventing hospitalizations and the need for intensive care associated with influenza pneumonia. VE was significantly higher against A (H1N1)pdm09 and was low against A (H3N2) and B.
Authors: Jill M Ferdinands; Manjusha Gaglani; Emily T Martin; Don Middleton; Arnold S Monto; Kempapura Murthy; Fernanda P Silveira; H Keipp Talbot; Richard Zimmerman; Elif Alyanak; Courtney Strickland; Sarah Spencer; Alicia M Fry Journal: J Infect Dis Date: 2019-09-13 Impact factor: 5.226
Authors: Carlos G Grijalva; Yuwei Zhu; Derek J Williams; Wesley H Self; Krow Ampofo; Andrew T Pavia; Chris R Stockmann; Jonathan McCullers; Sandra R Arnold; Richard G Wunderink; Evan J Anderson; Stephen Lindstrom; Alicia M Fry; Ivo M Foppa; Lyn Finelli; Anna M Bramley; Seema Jain; Marie R Griffin; Kathryn M Edwards Journal: JAMA Date: 2015-10-13 Impact factor: 56.272
Authors: Anna M Bramley; Sandra S Chaves; Fatimah S Dawood; Saumil Doshi; Arthur Reingold; Lisa Miller; Kimberly Yousey-Hindes; Monica M Farley; Patricia Ryan; Ruth Lynfield; Joan Baumbach; Shelley Zansky; Nancy Bennett; Ann Thomas; William Schaffner; Lyn Finelli; Seema Jain Journal: Public Health Rep Date: 2016 May-Jun Impact factor: 2.792
Authors: Mark W Tenforde; Jessie Chung; Emily R Smith; H Keipp Talbot; Christopher H Trabue; Richard K Zimmerman; Fernanda P Silveira; Manjusha Gaglani; Kempapura Murthy; Arnold S Monto; Emily T Martin; Huong Q McLean; Edward A Belongia; Lisa A Jackson; Michael L Jackson; Jill M Ferdinands; Brendan Flannery; Manish M Patel Journal: Clin Infect Dis Date: 2021-08-02 Impact factor: 20.999
Authors: Romina Abelleira; Alberto Ruano-Ravina; Adriana Lama; Gema Barbeito; María E Toubes; Cristina Domínguez-Antelo; Francisco J González-Barcala; Nuria Rodríguez-Núñez; Pedro J Marcos; María L Pérez Del Molino; Luis Valdés Journal: Can Respir J Date: 2019-03-17 Impact factor: 2.409